Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 16, 2025, Cellectis (CLLS) has a market cap of $0.18 billion USD. According to our data, Cellectis is ranked No.7067 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 16, 2025 | $0.18 B |
1.58%
|
| Dec 31, 2024 | $0.18 B |
-41.56%
|
| Dec 29, 2023 | $0.31 B |
46.67%
|
| Dec 30, 2022 | $0.21 B |
-74.14%
|
| Dec 31, 2021 | $0.81 B |
-69.99%
|
| Dec 31, 2020 | $2.71 B |
58.06%
|
| Dec 31, 2019 | $1.71 B |
2.82%
|
| Dec 31, 2018 | $1.67 B |
-42.88%
|
| Dec 29, 2017 | $2.92 B |
71.98%
|
| Dec 30, 2016 | $1.70 B |
-45.38%
|
| Dec 31, 2015 | $3.11 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Editas Medicine
EDIT
|
$0.11 B |
0.000 M
|
USA
|
 Intellia Therapeutics
NTLA
|
$0.76 B |
-0.000 M
|
USA
|
 Sangamo Therapeutics
SGMO
|
$0.17 B |
0.000 M
|
USA
|
 bluebird bio
BLUE
|
$43.76 M |
0.000 M
|
USA
|
 Fate Therapeutics
FATE
|
$0.13 B |
0.000 M
|
USA
|
 Allogene Therapeutics
ALLO
|
$0.32 B |
0.000 M
|
USA
|
 Beam Therapeutics
BEAM
|
$1.63 B |
-0.096 B
|
USA
|
 Precision BioSciences
DTIL
|
$57.86 M |
0.000 M
|
USA
|
 Poseida Therapeutics
PSTX
|
$0.93 B |
0.000 M
|
USA
|
 Verve Therapeutics
VERV
|
$0.44 B |
-0.000 M
|
USA
|
| Market Cap | = | CLLS Stock Price | * | CLLS Shares Outstanding |
| = | $1.46 | * | 0.10 B | |
| = | $0.18 B |